CHeCS is the first comprehensive U.S. longitudinal observational cohort of approximately 20,000 patients with chronic viral hepatitis B (5,000 patients) and C (15,000 patients). This study has generated publications and presentations addressing issues important to hepatitis care and treatment. Data from CHeCS have enhanced understanding of disease morbidity and mortality in the United States.
CHeCS data have been used to project the number of persons at highest or high priority for HCV antiviral treatment according to treatment guidance issued by AASLD, the Infectious Diseases Society of America, and the International Antiviral Society, United States. This information has informed discussions regarding the subset of people among the estimated 3.2 million people with chronic HCV infection, who should be prioritized to receive the newly available oral therapies.
The project has continued to complete analyses and develop manuscripts critical to understanding care and treatment of HCV and HBV. These analyses have included evaluation of HCV mortality among persons in care, hospitalizations among persons with chronic hepatitis, and the cost-effectiveness of treatment strategies for persons with HCV at different levels of liver disease (ranging from none to decompensated cirrhosis).
During 2014, CHeCS investigators published ten articles in peer-reviewed journals, with three more articles prepared for publication, in addition making many presentations at scientific and medical conferences.
The CHeCS project is supported by Gilead Sciences, AbbVie, and Janssen Therapeutics. Past funders have included: Vertex Pharmaceuticals; Genentech, a member of the Roche Group; and Bristol-Myers Squibb.